Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Verrica Pharmaceuticals's Ycanth offers superior efficacy to Novan, says Needham » 09:18
06/17/21
06/17
09:18
06/17/21
09:18
VRCA

Verrica Pharmaceuticals

$12.38 /

+0.6 (+5.09%)

, NOVN

Novan

$13.70 /

-1.62 (-10.57%)

Needham analyst Serge…

Needham analyst Serge Belanger keeps his Buy rating and $22 price target on Verica Pharma (VRCA) after a recent phase 3 study report by its competitor Novan (NOVN) for SB206 - a topical once-daily antiviral gel in development as a treatment for molluscum contagiosium. The trial met its primary endpoint and positions Novan to seek FDA approval of SB206 for what is expected to be an at-home, self or caregiver-applied treatment for molluscum, but Verica's Ycanth phase 3 results demonstrate a more consistent and much superior efficacy profile in clearing molluscum lesions, Belanger tells investors in a research note.

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$12.38 /

+0.6 (+5.09%)

NOVN Novan
$13.70 /

-1.62 (-10.57%)

VRCA Verrica Pharmaceuticals
$12.38 /

+0.6 (+5.09%)

06/01/21 Northland
Verrica Pharmaceuticals price target lowered to $19 from $24 at Northland
05/13/21 RBC Capital
Verrica Pharmaceuticals initiated with an Outperform at RBC Capital
03/08/21 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $24 from $21 at H.C. Wainwright
12/24/20 Cowen
Verrica approval for molluscum likely in Q3 of 2021, says Cowen
NOVN Novan
$13.70 /

-1.62 (-10.57%)

06/14/21 H.C. Wainwright
Novan price target raised to $28 from $20 at H.C. Wainwright
06/11/21 Roth Capital
Novan price target raised to $40 from $26 at Roth Capital
04/22/21
Fly Intel: Top five analyst initiations
04/22/21 Roth Capital
Roth Capital bullish on Novan, initiates with a Buy
VRCA Verrica Pharmaceuticals
$12.38 /

+0.6 (+5.09%)

  • 17
    Jun
  • 23
    Mar
VRCA Verrica Pharmaceuticals
$12.38 /

+0.6 (+5.09%)

NOVN Novan
$13.70 /

-1.62 (-10.57%)

VRCA Verrica Pharmaceuticals
$12.38 /

+0.6 (+5.09%)

Over a week ago
Recommendations
Verrica Pharmaceuticals price target lowered to $19 from $24 at Northland » 09:12
06/01/21
06/01
09:12
06/01/21
09:12
VRCA

Verrica Pharmaceuticals

$11.26 /

-0.51 (-4.33%)

Northland analyst Tim…

Northland analyst Tim Chiang lowered the firm's price target on Verrica Pharmaceuticals to $19 from $24 in a note published on Friday after the company announced that the FDA's review of VP-102 would be extended by three months to near the end of September. He has adjusted his 2021 estimates to reflect a delay in the expected approval and launch of the company's drug/device combo for treatment of molluscum and keeps an Outperform rating on Verrica shares.

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$11.26 /

-0.51 (-4.33%)

VRCA Verrica Pharmaceuticals
$11.26 /

-0.51 (-4.33%)

05/13/21 RBC Capital
Verrica Pharmaceuticals initiated with an Outperform at RBC Capital
03/08/21 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $24 from $21 at H.C. Wainwright
12/24/20 Cowen
Verrica approval for molluscum likely in Q3 of 2021, says Cowen
12/24/20 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $21 from $18 at H.C. Wainwright
VRCA Verrica Pharmaceuticals
$11.26 /

-0.51 (-4.33%)

  • 23
    Mar
VRCA Verrica Pharmaceuticals
$11.26 /

-0.51 (-4.33%)

VRCA Verrica Pharmaceuticals
$11.26 /

-0.51 (-4.33%)

Hot Stocks
Verrica announces extension of FDA review period for VP-102 NDA » 07:31
05/28/21
05/28
07:31
05/28/21
07:31
VRCA

Verrica Pharmaceuticals

$11.83 /

+1.03 (+9.54%)

Verrica Pharmaceuticals…

Verrica Pharmaceuticals announced that the U.S. Food and Drug Administration has extended the review period for the New Drug Application for VP-102 for the treatment of molluscum contagiosum. The Prescription Drug User Fee Act goal date has been extended by three months to September 23, 2021. The FDA extended the PDUFA goal date to allow the Agency to have additional time to review information submitted by Verrica, including its training program and distribution model, in response to comments from the agency regarding the Company's human factors study. On May 26, 2021, the FDA informed Verrica that the information submitted has been designated a major amendment, which allows FDA to take an additional three months to review the submitted information.

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$11.83 /

+1.03 (+9.54%)

VRCA Verrica Pharmaceuticals
$11.83 /

+1.03 (+9.54%)

05/13/21 RBC Capital
Verrica Pharmaceuticals initiated with an Outperform at RBC Capital
03/08/21 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $24 from $21 at H.C. Wainwright
12/24/20 Cowen
Verrica approval for molluscum likely in Q3 of 2021, says Cowen
12/24/20 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $21 from $18 at H.C. Wainwright
VRCA Verrica Pharmaceuticals
$11.83 /

+1.03 (+9.54%)

  • 23
    Mar
VRCA Verrica Pharmaceuticals
$11.83 /

+1.03 (+9.54%)

VRCA Verrica Pharmaceuticals
$11.83 /

+1.03 (+9.54%)

Over a month ago
Initiation
Verrica Pharmaceuticals initiated with an Outperform at RBC Capital » 16:20
05/13/21
05/13
16:20
05/13/21
16:20
VRCA

Verrica Pharmaceuticals

$11.67 /

+0.11 (+0.95%)

RBC Capital analyst…

RBC Capital analyst Daniel Busby initiated coverage of Verrica Pharmaceuticals with an Outperform rating and $19 price target. Verrica's lead product, YCANTH, has the potential to supplant compounded cantharidin in "several important dermatology markets," argues Busby. He forecasts combined peak sales for YCANTH of about $500M across three indications and sees an "attractive entry point" ahead of the company's upcoming PDUFA date on June 23, Busby added.

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$11.67 /

+0.11 (+0.95%)

VRCA Verrica Pharmaceuticals
$11.67 /

+0.11 (+0.95%)

03/08/21 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $24 from $21 at H.C. Wainwright
12/24/20 Cowen
Verrica approval for molluscum likely in Q3 of 2021, says Cowen
12/24/20 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $21 from $18 at H.C. Wainwright
07/15/20 BofA
Verrica Pharmaceuticals downgraded to Neutral from Buy at BofA
VRCA Verrica Pharmaceuticals
$11.67 /

+0.11 (+0.95%)

  • 23
    Mar
VRCA Verrica Pharmaceuticals
$11.67 /

+0.11 (+0.95%)

VRCA Verrica Pharmaceuticals
$11.67 /

+0.11 (+0.95%)

Hot Stocks
Verrica Pharmaceuticals assigned PDUFA goal date of June 23, partners with Torii » 07:44
05/07/21
05/07
07:44
05/07/21
07:44
VRCA

Verrica Pharmaceuticals

$11.52 /

-0.38 (-3.19%)

Verrica Pharmaceuticals…

Verrica Pharmaceuticals continued to expand its U.S. commercial operations during the quarter in preparation for the potential FDA approval of VP-102. The company has been assigned a Prescription Drug User Fee Act goal date of June 23, 2021 for its NDA for VP-102. If approved, VP-102 will be marketed in the United States under the conditionally accepted brand name YCANTH. The company entered into a Collaboration and License Agreement with Torii Pharmaceutical granting Torii an exclusive license to develop and commercialize VP-102 in Japan for the treatment of molluscum and common warts. Under the terms of the agreement, Torii made an up-front payment of $11.5M to Verrica and has also agreed to make up to an additional $58M in aggregate payments contingent on achievement of specified development, regulatory, and sales milestones. Torii will also make tiered transfer price payments for supply of product in the range of the mid-30s to mid-40s as a percent of net sales.

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$11.52 /

-0.38 (-3.19%)

VRCA Verrica Pharmaceuticals
$11.52 /

-0.38 (-3.19%)

03/08/21 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $24 from $21 at H.C. Wainwright
12/24/20 Cowen
Verrica approval for molluscum likely in Q3 of 2021, says Cowen
12/24/20 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $21 from $18 at H.C. Wainwright
07/15/20 BofA
Verrica Pharmaceuticals downgraded to Neutral from Buy at BofA
VRCA Verrica Pharmaceuticals
$11.52 /

-0.38 (-3.19%)

  • 23
    Mar
VRCA Verrica Pharmaceuticals
$11.52 /

-0.38 (-3.19%)

VRCA Verrica Pharmaceuticals
$11.52 /

-0.38 (-3.19%)

Earnings
Verrica Pharmaceuticals reports Q1 EPS (4c), consensus (35c) » 07:39
05/07/21
05/07
07:39
05/07/21
07:39
VRCA

Verrica Pharmaceuticals

$11.52 /

-0.38 (-3.19%)

Reports Q1 licensing…

Reports Q1 licensing revenues 12M. "This is a significant time for the company as we ramp up our commercial readiness plans in preparation for potential FDA approval this year of VP-102 for the treatment of molluscum, a common, highly contagious skin disease with no FDA-approved treatments," said Ted White, Verrica's President and CEO. "In parallel, we strengthened our financial position, raising funds and generating licensing revenues that we believe will support planned operations at least through the second quarter of 2023."

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$11.52 /

-0.38 (-3.19%)

VRCA Verrica Pharmaceuticals
$11.52 /

-0.38 (-3.19%)

03/08/21 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $24 from $21 at H.C. Wainwright
12/24/20 Cowen
Verrica approval for molluscum likely in Q3 of 2021, says Cowen
12/24/20 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $21 from $18 at H.C. Wainwright
07/15/20 BofA
Verrica Pharmaceuticals downgraded to Neutral from Buy at BofA
VRCA Verrica Pharmaceuticals
$11.52 /

-0.38 (-3.19%)

  • 23
    Mar
VRCA Verrica Pharmaceuticals
$11.52 /

-0.38 (-3.19%)

VRCA Verrica Pharmaceuticals
$11.52 /

-0.38 (-3.19%)

Options
new option listings and one option delisting on May 5th » 08:30
05/05/21
05/05
08:30
05/05/21
08:30
AIQ

Alliance HealthCare

$28.51 /

-0.66 (-2.26%)

, ASEA

Aegean Sea

$14.66 /

-0.185 (-1.25%)

, BTX

Brooklyn ImmunoTherapeutics

$54.73 /

-21.32 (-28.03%)

, CIGI

Colliers International

$115.70 /

+6.09 (+5.56%)

, DOOO

BRP Inc.

$90.90 /

-1.6 (-1.73%)

, EDR

Endeavor Group

$29.99 /

-0.785 (-2.55%)

, ELDN

Eledon Pharmaceuticals

$9.85 /

-0.05 (-0.51%)

, FLUX

Flux Power

$10.44 /

-0.505 (-4.61%)

, FSV

FirstService

$159.97 /

-2.31 (-1.42%)

, GWRS

Global Water Resources

$16.50 /

-0.67 (-3.90%)

, MYMD

MyMD Pharmaceuticals

$4.20 /

-0.01 (-0.24%)

, NEBC

Nebula Caravel Acquisition

$9.90 /

+ (+0.00%)

, SLGL

Sol-Gel Technologies

$10.51 /

-0.19 (-1.78%)

, TARA

Protara Therapeutics

$10.43 /

-0.76 (-6.79%)

, VRCA

Verrica Pharmaceuticals

$12.27 /

-0.08 (-0.65%)

New option listings for…

New option listings for May 5th include Global X Funds Global X Future Analytics Tech ETF (AIQ), Global X SuperDividend Alternatives (ALTY), Global X Southeast Asia (ASEA), Aspirational Consumer Lifestyle Corp (Class A Stock) (ASPL), Brooklyn ImmunoTherapeutics Inc (BTX), Global X MSCI China Information Technology ETF (CHIK), Colliers International (CIGI), BRP Inc (DOOO), Endeavor Group Holdings Inc (Class A Stock) (EDR), Eledon Pharmaceuticals Inc (ELDN), Fidelity Momentum Factor ETF (FDMO), Fidelity Dividend ETF for Rising Rates (FDRR), Fidelity Core Dividend ETF (FDVV), Fidelity International High Dividend ETF (FIDI), Flux Power Holdings Inc (FLUX), Fidelity Quality Factor ETF (FQAL), Fidelity Small Mid Multifactor ETF (FSMD), FirstService (FSV), Fidelity Value Factor ETF (FVAL), Global Water Resources (GWRS), Global X Thematic Growth ETF (GXTG), Direxion Daily S&P 500 High Beta Bull 3x Shares (HIBL), Global X Conscious Companies (KRMA), Global X Millennials Thematic (MILN), MyMD Pharmaceuticals Inc (MYMD), Nebula Caravel Acquisition Corporation (Class A Stock) (NEBC), Fidelity Nasdaq Composite Index (ONEQ), First Trust Nasdaq Artificial Intelligence and Robotics (ROBT), Global X SuperDividend Emerging Markets ETF (SDEM), Sol Gel Technologies Ltd (SLGL), SVF Investment Corporation (Class A Stock) (SVFA), Protara Therapeutics Inc (TARA), Verrica Parmaceuticals Inc (VRCA), Direxion Daily Consumer Discretionary Bull 3x Shares (WANT), Direxion Daily Dow Jones Internet Bull 3x Shares (WEBL), and Global X S&P 500 Covered Call ETF (XYLD). Option delistings effective May 5th include Valaris Plc (VALPQ).

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$12.27 /

-0.08 (-0.65%)

TARA Protara Therapeutics
$10.43 /

-0.76 (-6.79%)

SLGL Sol-Gel Technologies
$10.51 /

-0.19 (-1.78%)

NEBC Nebula Caravel Acquisition
$9.90 /

+ (+0.00%)

MYMD MyMD Pharmaceuticals
$4.20 /

-0.01 (-0.24%)

GWRS Global Water Resources
$16.50 /

-0.67 (-3.90%)

FSV FirstService
$159.97 /

-2.31 (-1.42%)

FLUX Flux Power
$10.44 /

-0.505 (-4.61%)

ELDN Eledon Pharmaceuticals
$9.85 /

-0.05 (-0.51%)

DOOO BRP Inc.
$90.90 /

-1.6 (-1.73%)

CIGI Colliers International
$115.70 /

+6.09 (+5.56%)

BTX Brooklyn ImmunoTherapeutics
$54.73 /

-21.32 (-28.03%)

AIQ Alliance HealthCare
$28.51 /

-0.66 (-2.26%)

ASEA Aegean Sea
$14.66 /

-0.185 (-1.25%)

BTX Brooklyn ImmunoTherapeutics
$54.73 /

-21.32 (-28.03%)

CIGI Colliers International
$115.70 /

+6.09 (+5.56%)

02/16/21 TD Securities
Colliers International price target raised to $125 from $100 at TD Securities
02/16/21 RBC Capital
Colliers International price target raised to $126 from $96 at RBC Capital
02/16/21 RBC Capital
Colliers International price target raised to $126 from $96 at RBC Capital
01/25/21
Fly Intel: Top five analyst initiations
DOOO BRP Inc.
$90.90 /

-1.6 (-1.73%)

04/26/21 Citi
BRP Inc. initiated with a Buy at Citi
04/06/21 Stifel
BRP Inc. downgraded to Hold from Buy at Stifel
03/29/21 Desjardins
BRP Inc. price target raised to C$131 from C$107 at Desjardins
03/26/21 CIBC
BRP Inc. price target raised to C$117 from C$100 at CIBC
EDR Endeavor Group
$29.99 /

-0.785 (-2.55%)

ELDN Eledon Pharmaceuticals
$9.85 /

-0.05 (-0.51%)

03/23/21
Fly Intel: Top five analyst initiations
03/23/21 Cantor Fitzgerald
Eledon Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
03/22/21 Cantor Fitzgerald
Eledon Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
02/08/21 SVB Leerink
SVB Leerink bullish on Eledon Pharmaceuticals, initiates with an Outperform
FLUX Flux Power
$10.44 /

-0.505 (-4.61%)

02/04/21
Fly Intel: Top five analyst initiations
02/04/21
Flux Power initiated with a Buy at Maxim
10/12/20 Roth Capital
Flux Power initiated with a Buy at Roth Capital
FSV FirstService
$159.97 /

-2.31 (-1.42%)

04/28/21 Raymond James
Raymond James downgrades FirstService to Market Perform on 'healthy valuation'
04/28/21 Raymond James
FirstService downgraded to Market Perform from Outperform at Raymond James
04/28/21
Fly Intel: Top five analyst downgrades
04/28/21 TD Securities
FirstService downgraded to Hold from Buy at TD Securities
GWRS Global Water Resources
$16.50 /

-0.67 (-3.90%)

02/25/21 Roth Capital
Global Water Resources price target raised to $19 from $12.50 at Roth Capital
MYMD MyMD Pharmaceuticals
$4.20 /

-0.01 (-0.24%)

NEBC Nebula Caravel Acquisition
$9.90 /

+ (+0.00%)

04/09/21
Fly Intel: Top five analyst initiations
04/09/21 Tigress Financial
Nebula Caravel Acquisition initiated with a Buy at Tigress Financial
03/19/21
Fly Intel: Top five analyst initiations
03/19/21 DA Davidson
Rover initiated with a Buy at DA Davidson amid COVID-related tailwinds
SLGL Sol-Gel Technologies
$10.51 /

-0.19 (-1.78%)

TARA Protara Therapeutics
$10.43 /

-0.76 (-6.79%)

04/26/21 Oppenheimer
Protara Therapeutics price target lowered to $32 from $43 at Oppenheimer
10/19/20 Cowen
Protara Therapeutics initiated with an Outperform at Cowen
07/29/20
Fly Intel: Top five analyst initiations
07/29/20 Guggenheim
Protara Therapeutics started with Buy rating, $50 target at Guggenheim
VRCA Verrica Pharmaceuticals
$12.27 /

-0.08 (-0.65%)

03/08/21 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $24 from $21 at H.C. Wainwright
12/24/20 Cowen
Verrica approval for molluscum likely in Q3 of 2021, says Cowen
12/24/20 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $21 from $18 at H.C. Wainwright
07/15/20 BofA
Verrica Pharmaceuticals downgraded to Neutral from Buy at BofA
VRCA Verrica Pharmaceuticals
$12.27 /

-0.08 (-0.65%)

TARA Protara Therapeutics
$10.43 /

-0.76 (-6.79%)

SLGL Sol-Gel Technologies
$10.51 /

-0.19 (-1.78%)

FSV FirstService
$159.97 /

-2.31 (-1.42%)

FLUX Flux Power
$10.44 /

-0.505 (-4.61%)

ELDN Eledon Pharmaceuticals
$9.85 /

-0.05 (-0.51%)

CIGI Colliers International
$115.70 /

+6.09 (+5.56%)

  • 29
    Apr
  • 23
    Mar
  • 22
    Sep
DOOO BRP Inc.
$90.90 /

-1.6 (-1.73%)

VRCA Verrica Pharmaceuticals
$12.27 /

-0.08 (-0.65%)

NEBC Nebula Caravel Acquisition
$9.90 /

+ (+0.00%)

EDR Endeavor Group
$29.99 /

-0.785 (-2.55%)

BTX Brooklyn ImmunoTherapeutics
$54.73 /

-21.32 (-28.03%)

Syndicate
Verrica Pharmaceuticals 2.034M share Spot Secondary priced at $14.75 » 06:14
03/23/21
03/23
06:14
03/23/21
06:14
VRCA

Verrica Pharmaceuticals

$16.54 /

+0.445 (+2.77%)

Jefferies, Cowen and RBC…

Jefferies, Cowen and RBC Capital acted as joint book running managers for the offering.

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$16.54 /

+0.445 (+2.77%)

VRCA Verrica Pharmaceuticals
$16.54 /

+0.445 (+2.77%)

03/08/21 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $24 from $21 at H.C. Wainwright
12/24/20 Cowen
Verrica approval for molluscum likely in Q3 of 2021, says Cowen
12/24/20 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $21 from $18 at H.C. Wainwright
07/15/20 BofA
Verrica Pharmaceuticals downgraded to Neutral from Buy at BofA
VRCA Verrica Pharmaceuticals
$16.54 /

+0.445 (+2.77%)

  • 23
    Mar
VRCA Verrica Pharmaceuticals
$16.54 /

+0.445 (+2.77%)

Over a quarter ago
On The Fly
Fly Intel: After-Hours Movers » 18:38
03/22/21
03/22
18:38
03/22/21
18:38
BLFS

BioLife Solutions

$38.52 /

-0.33 (-0.85%)

, GHLD

Guild Holdings

$15.23 /

+0.4 (+2.70%)

, KODK

Eastman Kodak

$8.25 /

-0.06 (-0.72%)

, DSP

Viant

$59.34 /

+7.11 (+13.61%)

, RAVN

Raven

$36.06 /

-0.48 (-1.31%)

, IONS

Ionis Pharmaceuticals

$55.63 /

+1.39 (+2.56%)

, XGN

Exagen

$19.83 /

-0.17 (-0.85%)

, QS

QuantumScape

$64.19 /

+4.93 (+8.32%)

, PLL

Piedmont Lithium

$81.70 /

+2.95 (+3.75%)

, MP

MP Materials

$45.20 /

-0.79 (-1.72%)

, WES

Western Midstream

$18.27 /

-0.225 (-1.22%)

, VRCA

Verrica Pharmaceuticals

$16.54 /

+0.445 (+2.77%)

Check out this evening's…

ShowHide Related Items >><<
XGN Exagen
$19.83 /

-0.17 (-0.85%)

WES Western Midstream
$18.27 /

-0.225 (-1.22%)

VRCA Verrica Pharmaceuticals
$16.54 /

+0.445 (+2.77%)

RAVN Raven
$36.06 /

-0.48 (-1.31%)

QS QuantumScape
$64.19 /

+4.93 (+8.32%)

PLL Piedmont Lithium
$81.70 /

+2.95 (+3.75%)

MP MP Materials
$45.20 /

-0.79 (-1.72%)

KODK Eastman Kodak
$8.25 /

-0.06 (-0.72%)

IONS Ionis Pharmaceuticals
$55.63 /

+1.39 (+2.56%)

GHLD Guild Holdings
$15.23 /

+0.4 (+2.70%)

BLFS BioLife Solutions
$38.52 /

-0.33 (-0.85%)

BLFS BioLife Solutions
$38.52 /

-0.33 (-0.85%)

12/28/20 Northland
BioLife Solutions price target raised to $55 from $35 at Northland
11/09/20 KeyBanc
BioLife Solutions initiated with an Overweight at KeyBanc
10/19/20 B. Riley
BioLife Solutions price target raised to $35.50 from $30 at B. Riley Securities
09/23/20 B. Riley
BioLife Solutions price target raised to $30 from $25.50 at B. Riley FBR
GHLD Guild Holdings
$15.23 /

+0.4 (+2.70%)

01/19/21 JPMorgan
Guild Holdings downgraded to Neutral with $18.50 target at JPMorgan
01/19/21 JPMorgan
Guild Holdings downgraded to Neutral from Overweight at JPMorgan
11/16/20
Fly Intel: Top five analyst initiations
11/16/20 Compass Point
Compass Point starts Guild Holdings at Buy with $20 price target
KODK Eastman Kodak
$8.25 /

-0.06 (-0.72%)

DSP Viant
$59.34 /

+7.11 (+13.61%)

03/08/21
Fly Intel: Top five analyst initiations
03/08/21 Raymond James
Viant initiated with a Market Perform at Raymond James
03/08/21 Canaccord
Viant initiated with a Buy, $52 price target at Canaccord
03/08/21 Needham
Viant initiated with a Buy at Needham
RAVN Raven
$36.06 /

-0.48 (-1.31%)

03/19/21 Lake Street
Raven initiated with a Buy at Lake Street
06/19/20
Fly Intel: Top five analyst initiations
06/19/20 Oppenheimer
Raven initiated with an Outperform at Oppenheimer
06/18/20 Oppenheimer
Raven initiated with an Outperform at Oppenheimer
IONS Ionis Pharmaceuticals
$55.63 /

+1.39 (+2.56%)

03/01/21 Barclays
Ionis Pharmaceuticals upgraded to Equal Weight from Underweight at Barclays
02/24/21 Piper Sandler
Ionis Pharmaceuticals price target lowered to $55 from $60 at Piper Sandler
12/28/20 Piper Sandler
Ionis partner data inconclusive in Huntington's disease, says Piper Sandler
12/24/20 Benchmark
Ionis starting to be treated as M&A target, says Benchmark
XGN Exagen
$19.83 /

-0.17 (-0.85%)

03/17/21 Cowen
Exagen price target raised to $26 from $21 at Cowen
12/29/20 Cantor Fitzgerald
Exagen amended Janssen terms removes uncertainty, says Cantor Fitzgerald
11/09/20 KeyBanc
Exagen initiated with an Overweight at KeyBanc
10/07/20 BTIG
Exagen assumed with a Buy at BTIG
QS QuantumScape
$64.19 /

+4.93 (+8.32%)

03/08/21 Cowen
Cowen bullish on battery technology, starts QuantumScape at Outperform
03/08/21 Cowen
QuantumScape initiated with an Outperform at Cowen
03/04/21 Baird
QuantumScape initiated with a Neutral at Baird
02/11/21 Morgan Stanley
QuantumScape initiated with an Overweight at Morgan Stanley
PLL Piedmont Lithium
$81.70 /

+2.95 (+3.75%)

03/04/21 B. Riley
Piedmont Lithium price target raised to $93 from $66 at B. Riley Securities
02/09/21 Evercore ISI
Evercore boosts Piedmont Lithium target to $75, sees path to $90 per share
01/25/21 B. Riley
Piedmont Lithium initiated with a Buy at B. Riley Securities
01/22/21
Fly Intel: Top five analyst initiations
MP MP Materials
$45.20 /

-0.79 (-1.72%)

03/10/21 Cowen
MP Materials initiated with an Outperform at Cowen
03/09/21 Deutsche Bank
MP Materials downgraded to Hold on valuation at Deutsche Bank
03/08/21 Deutsche Bank
MP Materials downgraded to Hold from Buy at Deutsche Bank
03/02/21
Fly Intel: Top five analyst initiations
WES Western Midstream
$18.27 /

-0.225 (-1.22%)

03/12/21 JPMorgan
Western Midstream upgraded to Overweight from Neutral at JPMorgan
03/05/21 Barclays
Western Midstream price target raised to $22 from $19 at Barclays
02/01/21 Scotiabank
Western Midstream resumed with a Sector Perform at Scotiabank
01/26/21 BofA
Western Midstream upgraded to Neutral from Underperform at BofA
VRCA Verrica Pharmaceuticals
$16.54 /

+0.445 (+2.77%)

03/08/21 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $24 from $21 at H.C. Wainwright
12/24/20 Cowen
Verrica approval for molluscum likely in Q3 of 2021, says Cowen
12/24/20 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $21 from $18 at H.C. Wainwright
07/15/20 BofA
Verrica Pharmaceuticals downgraded to Neutral from Buy at BofA
XGN Exagen
$19.83 /

-0.17 (-0.85%)

WES Western Midstream
$18.27 /

-0.225 (-1.22%)

VRCA Verrica Pharmaceuticals
$16.54 /

+0.445 (+2.77%)

RAVN Raven
$36.06 /

-0.48 (-1.31%)

MP MP Materials
$45.20 /

-0.79 (-1.72%)

KODK Eastman Kodak
$8.25 /

-0.06 (-0.72%)

IONS Ionis Pharmaceuticals
$55.63 /

+1.39 (+2.56%)

GHLD Guild Holdings
$15.23 /

+0.4 (+2.70%)

DSP Viant
$59.34 /

+7.11 (+13.61%)

BLFS BioLife Solutions
$38.52 /

-0.33 (-0.85%)

  • 25
    Mar
  • 24
    Mar
  • 23
    Mar
  • 23
    Mar
  • 23
    Mar
  • 24
    Mar
  • 10
    Feb
  • 22
    Oct
  • 22
    Oct
  • 02
    Jul
  • 09
    Jun
QS QuantumScape
$64.19 /

+4.93 (+8.32%)

KODK Eastman Kodak
$8.25 /

-0.06 (-0.72%)

WES Western Midstream
$18.27 /

-0.225 (-1.22%)

RAVN Raven
$36.06 /

-0.48 (-1.31%)

QS QuantumScape
$64.19 /

+4.93 (+8.32%)

PLL Piedmont Lithium
$81.70 /

+2.95 (+3.75%)

MP MP Materials
$45.20 /

-0.79 (-1.72%)

KODK Eastman Kodak
$8.25 /

-0.06 (-0.72%)

IONS Ionis Pharmaceuticals
$55.63 /

+1.39 (+2.56%)

GHLD Guild Holdings
$15.23 /

+0.4 (+2.70%)

DSP Viant
$59.34 /

+7.11 (+13.61%)

BLFS BioLife Solutions
$38.52 /

-0.33 (-0.85%)

QS QuantumScape
$64.19 /

+4.93 (+8.32%)

PLL Piedmont Lithium
$81.70 /

+2.95 (+3.75%)

MP MP Materials
$45.20 /

-0.79 (-1.72%)

KODK Eastman Kodak
$8.25 /

-0.06 (-0.72%)

Syndicate
Verrica Pharmaceuticals $30M Spot Secondary re-offered at $14.75 » 16:27
03/22/21
03/22
16:27
03/22/21
16:27
VRCA

Verrica Pharmaceuticals

$16.54 /

+0.445 (+2.77%)

Jefferies, Cowen and RBC…

Jefferies, Cowen and RBC Capital are acting as joint book running managers for the offering.

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$16.54 /

+0.445 (+2.77%)

VRCA Verrica Pharmaceuticals
$16.54 /

+0.445 (+2.77%)

03/08/21 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $24 from $21 at H.C. Wainwright
12/24/20 Cowen
Verrica approval for molluscum likely in Q3 of 2021, says Cowen
12/24/20 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $21 from $18 at H.C. Wainwright
07/15/20 BofA
Verrica Pharmaceuticals downgraded to Neutral from Buy at BofA
VRCA Verrica Pharmaceuticals
$16.54 /

+0.445 (+2.77%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.